Repligen (RGEN)
Market Price (4/12/2026): $120.08 | Market Cap: $6.8 BilSector: Health Care | Industry: Biotechnology
Repligen (RGEN)
Market Price (4/12/2026): $120.08Market Cap: $6.8 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% Low stock price volatilityVol 12M is 46% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, mRNA Technology, Show more. | Weak multi-year price returns2Y Excs Rtn is -62%, 3Y Excs Rtn is -92% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 81x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 58x, P/EPrice/Earnings or Price/(Net Income) is 138x Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.5% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.2% Key risksRGEN key risks include [1] a dependence on a limited number of suppliers for critical components, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Low stock price volatilityVol 12M is 46% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, mRNA Technology, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -62%, 3Y Excs Rtn is -92% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 81x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 58x, P/EPrice/Earnings or Price/(Net Income) is 138x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.5% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.2% |
| Key risksRGEN key risks include [1] a dependence on a limited number of suppliers for critical components, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Repligen (RGEN) stock has lost about 25% since 12/31/2025 because of the following key factors:
1. Repligen's 2026 financial guidance was perceived as cautious by investors, despite beating Q4 2025 earnings and revenue estimates. The company guided for full-year 2026 revenue between $810 million and $840 million, representing 9% to 13% organic growth. This outlook tempered investor expectations, leading to a reassessment of the stock's future potential.
2. A notable "gene therapy platform drag" significantly impacted the 2026 outlook. Repligen explicitly projected a "multi-point" headwind, estimated at approximately 2-3 percentage points, on its overall 2026 revenue growth guidance. This specific issue was also expected to negatively affect the Filtration segment by roughly 3 percentage points, a category that constitutes about 55% of the company's total revenue.
Show more
1. Repligen's 2026 financial guidance was perceived as cautious by investors, despite beating Q4 2025 earnings and revenue estimates. The company guided for full-year 2026 revenue between $810 million and $840 million, representing 9% to 13% organic growth. This outlook tempered investor expectations, leading to a reassessment of the stock's future potential.
2. A notable "gene therapy platform drag" significantly impacted the 2026 outlook. Repligen explicitly projected a "multi-point" headwind, estimated at approximately 2-3 percentage points, on its overall 2026 revenue growth guidance. This specific issue was also expected to negatively affect the Filtration segment by roughly 3 percentage points, a category that constitutes about 55% of the company's total revenue.
Show more
Stock Movement Drivers
Fundamental Drivers
The -26.7% change in RGEN stock from 12/31/2025 to 4/11/2026 was primarily driven by a -97.4% change in the company's P/E Multiple.| (LTM values as of) | 12312025 | 4112026 | Change |
|---|---|---|---|
| Stock Price ($) | 163.86 | 120.10 | -26.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 708 | 738 | 4.3% |
| Net Income Margin (%) | 0.2% | 6.6% | 2597.5% |
| P/E Multiple | 5,304.7 | 138.3 | -97.4% |
| Shares Outstanding (Mil) | 56 | 56 | -0.1% |
| Cumulative Contribution | -26.7% |
Market Drivers
12/31/2025 to 4/11/2026| Return | Correlation | |
|---|---|---|
| RGEN | -26.7% | |
| Market (SPY) | -5.4% | 52.9% |
| Sector (XLV) | -4.8% | 38.1% |
Fundamental Drivers
The -10.2% change in RGEN stock from 9/30/2025 to 4/11/2026 was primarily driven by a -17.9% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4112026 | Change |
|---|---|---|---|
| Stock Price ($) | 133.67 | 120.10 | -10.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 674 | 738 | 9.5% |
| P/S Multiple | 11.2 | 9.2 | -17.9% |
| Shares Outstanding (Mil) | 56 | 56 | -0.1% |
| Cumulative Contribution | -10.2% |
Market Drivers
9/30/2025 to 4/11/2026| Return | Correlation | |
|---|---|---|
| RGEN | -10.2% | |
| Market (SPY) | -2.9% | 49.1% |
| Sector (XLV) | 6.3% | 51.6% |
Fundamental Drivers
The -5.6% change in RGEN stock from 3/31/2025 to 4/11/2026 was primarily driven by a -18.5% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4112026 | Change |
|---|---|---|---|
| Stock Price ($) | 127.24 | 120.10 | -5.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 634 | 738 | 16.4% |
| P/S Multiple | 11.2 | 9.2 | -18.5% |
| Shares Outstanding (Mil) | 56 | 56 | -0.4% |
| Cumulative Contribution | -5.6% |
Market Drivers
3/31/2025 to 4/11/2026| Return | Correlation | |
|---|---|---|
| RGEN | -5.6% | |
| Market (SPY) | 16.3% | 57.7% |
| Sector (XLV) | 2.3% | 56.6% |
Fundamental Drivers
The -28.7% change in RGEN stock from 3/31/2023 to 4/11/2026 was primarily driven by a -71.5% change in the company's Net Income Margin (%).| (LTM values as of) | 3312023 | 4112026 | Change |
|---|---|---|---|
| Stock Price ($) | 168.36 | 120.10 | -28.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 802 | 738 | -7.9% |
| Net Income Margin (%) | 23.2% | 6.6% | -71.5% |
| P/E Multiple | 50.3 | 138.3 | 175.1% |
| Shares Outstanding (Mil) | 56 | 56 | -1.4% |
| Cumulative Contribution | -28.7% |
Market Drivers
3/31/2023 to 4/11/2026| Return | Correlation | |
|---|---|---|
| RGEN | -28.7% | |
| Market (SPY) | 63.3% | 44.6% |
| Sector (XLV) | 19.1% | 42.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RGEN Return | 38% | -36% | 6% | -20% | 14% | -27% | -37% |
| Peers Return | 48% | -19% | -4% | -3% | -1% | -12% | -4% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| RGEN Win Rate | 67% | 25% | 50% | 33% | 58% | 25% | |
| Peers Win Rate | 79% | 40% | 50% | 46% | 50% | 31% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| RGEN Max Drawdown | -13% | -47% | -33% | -33% | -24% | -33% | |
| Peers Max Drawdown | -3% | -32% | -28% | -9% | -27% | -19% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: DHR, TMO, TECH, A. See RGEN Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)
How Low Can It Go
| Event | RGEN | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -64.8% | -25.4% |
| % Gain to Breakeven | 184.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -22.2% | -33.9% |
| % Gain to Breakeven | 28.5% | 51.3% |
| Time to Breakeven | 57 days | 148 days |
| 2018 Correction | ||
| % Loss | -32.9% | -19.8% |
| % Gain to Breakeven | 49.0% | 24.7% |
| Time to Breakeven | 134 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -51.9% | -56.8% |
| % Gain to Breakeven | 107.9% | 131.3% |
| Time to Breakeven | 1,276 days | 1,480 days |
Compare to DHR, TMO, TECH, A
In The Past
Repligen's stock fell -64.8% during the 2022 Inflation Shock from a high on 9/23/2021. A -64.8% loss requires a 184.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Repligen (RGEN)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
AI Analysis | Feedback
1. Intel for biological drug manufacturing
2. A specialized W.W. Grainger for biopharmaceutical manufacturing equipment and supplies
AI Analysis | Feedback
```html- Protein A Ligands: Binding components used in Protein A affinity chromatography resins.
- Cell Culture Growth Factor Products: Products that support and enhance cell growth in bioprocessing.
- OPUS Pre-packed Chromatography Columns: Columns used for the purification of biologics.
- OPUS Smaller-scale Columns: Used for high throughput process development screening, viral clearance validation, and scale-down validation.
- ELISA Test Kits: Diagnostic kits used for detecting and quantifying substances.
- CaptivA Chromatography Resins: Resins employed in chromatography for separation and purification processes.
- XCell Alternating Tangential Flow (ATF) Systems: Filtration devices utilized in upstream perfusion and cell culture processing.
- TangenX Flat Sheet Cassettes: Used in downstream biologic drug concentration and formulation processes.
- KrosFlo Tangential Flow Filtration (TFF) Systems: Systems designed for tangential flow filtration and tangential flow depth filtration.
- Spectra/Por Dialysis Products: Laboratory and process products for dialysis.
- SpectraFlo Dynamic Dialysis Systems: Systems used for dynamic dialysis applications.
- ProConnex Single-use Hollow Fiber: Single-use hollow fiber products for bioprocessing.
- SoloVPE, FlowVPE, and FlowVPX Slope Spectroscopy Systems: Process analytics systems used for real-time measurement and analysis.
AI Analysis | Feedback
nullAI Analysis | Feedback
Navigo Proteins GmbH
AI Analysis | Feedback
Olivier Loeillot, President and Chief Executive OfficerOlivier Loeillot became President and Chief Executive Officer of Repligen on September 1, 2024, having previously served as the Chief Commercial Officer since October 2023. Prior to joining Repligen, Mr. Loeillot held the position of Chief Executive Officer at Ascensus Specialties, a company specializing in the manufacture of specialty chemicals for the life sciences and pharmaceutical sectors.
Jason K. Garland, Chief Financial Officer
Jason K. Garland joined Repligen as Chief Financial Officer in September 2023. In this role, he is responsible for overseeing all corporate finance and audit functions, capital markets, mergers and acquisitions (M&A) transactions, financial planning and analysis, budgeting, risk management, information technology, and investor relations. Previously, Mr. Garland served as CFO for GE Industrial Solutions. He also holds a board position at Acutus Medical, a publicly traded medical device company.
James R. Bylund, Chief Operating Officer
James R. Bylund has served as Repligen’s Chief Operating Officer since January 2022, having initially joined the company in March 2020. Mr. Bylund possesses extensive experience in managing multiple global operating sites and scaling operations to meet increasing demand. He earned a B.S. in Accounting from Utah State University and an M.B.A. from Indiana University.
Ralf Kuriyel, Senior Vice President, Research & Development
Ralf Kuriyel joined Repligen in October 2016 and currently holds the position of Senior Vice President, Research & Development. In this capacity, he is responsible for overseeing the company's innovation programs, which include the strategic integration of acquired technologies.
Brian Douglass, Senior Vice President and Chief Product Officer
Brian Douglass assumed the role of Senior Vice President and Chief Product Officer at Repligen as of December 31, 2025. He previously served as Senior Vice President, Filtration and Chromatography, having joined Repligen in May 2024. Before his tenure at Repligen, Mr. Douglass was Vice President and General Manager of the Cell Biology franchise at Thermo Fisher Scientific. He also spent eight years at Cytiva (a Danaher company), where he held roles such as Global Head of Product Management and General Manager for the Cell Culture business.
AI Analysis | Feedback
Key Risks to Repligen (RGEN)
- Dependence on Biopharmaceutical Industry R&D and Manufacturing Trends: Repligen's business is highly dependent on the spending and investment levels within the biopharmaceutical, life sciences, and diagnostics industries. A slowdown in drug development, a decrease in R&D budgets by its customers, or shifts in bioprocessing manufacturing trends could directly and negatively impact the demand for Repligen's bioprocessing technologies and systems.
- Intense Competition and Rapid Technological Change: The market for bioprocessing technologies is competitive and characterized by rapid technological advancements. Repligen faces competition from other companies offering similar or alternative products and technologies for protein purification, cell culture, filtration, and process analytics. Failure to continually innovate, develop new products, or adapt to emerging technologies could lead to a loss of market share or render its existing products obsolete.
- Intellectual Property Protection: Repligen's competitive advantage relies significantly on its proprietary technologies, including its Protein A ligands, chromatography products, filtration systems, and process analytics solutions. The inability to protect its intellectual property, potential infringement by competitors, or challenges to its patents could erode its market position and profitability.
AI Analysis | Feedback
nullAI Analysis | Feedback
Repligen Corporation's main products and services operate within several significant addressable markets globally.
- Overall Bioprocessing Market: The total addressable market for Repligen, which focuses on bioprocessing technologies, was estimated at approximately $12 billion in 2024, a substantial increase from $4 billion in 2020. Another estimate for Repligen's addressable market expanded from approximately $3 billion in 2019 to over $13 billion in 2025. The broader global bioprocessing market size was valued at USD 33.21 billion in 2025 and is predicted to increase to approximately USD 124.42 billion by 2035, expanding at a CAGR of 14.12% from 2026 to 2035. North America held a 46.7% market share in the bioprocessing market in 2035.
- Protein A Ligands (and CaptivA Chromatography Resins): The global Protein A resin market was valued at USD 1.27 billion in 2025 and is estimated to grow to USD 2.08 billion by 2031, exhibiting a CAGR of 8.58% during the forecast period. Another report estimates the global Protein A resins market at USD 1.4 billion in 2025, projected to reach USD 2.5 billion in 2035, growing at a CAGR of 5.9%. North America commanded 40.50% of the Protein A resin market share in 2025.
- Cell Culture Growth Factor Products: The global growth factors market is estimated to grow from US$ 2.5 billion in 2026 to US$ 3.7 billion by 2033, recording a CAGR of 5.8%. North America leads this market with a 39.8% share in 2025. More broadly, the global cell culture market size is estimated at USD 32.23 billion in 2025 and is anticipated to reach around USD 83.96 billion by 2035, expanding at a CAGR of 10.05%. North America contributed approximately 42% of the cell culture market share in 2025.
- OPUS Pre-packed Chromatography Columns: The global prepacked chromatography columns market size was calculated at USD 3.54 billion in 2025 and is predicted to increase to approximately USD 5.55 billion by 2035, expanding at a CAGR of 4.60%. North America dominated this market with a major share in 2025, with revenue of USD 1.3 billion in 2023, projected to rise to USD 1.9 billion by 2032.
- ELISA Test Kits: The global ELISA kits market size is projected to grow from approximately $2.1 billion in 2023 to an estimated $3.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of around 6.5%. The global enzyme-linked immunosorbent assay (ELISA) testing market size is evaluated at USD 2.42 billion in 2025 and is expected to reach around USD 4.19 billion by 2034, growing at a CAGR of 6.32%. North America holds a significant share, with the U.S. market capturing 79.2% within North America in 2024.
- Filtration Products (XCell Alternating Tangential Flow systems, TangenX flat sheet cassettes, KrosFlo tangential flow filtration, ProConnex single-use hollow fiber): The global tangential flow filtration market size was valued at USD 2.05 billion in 2024 and is expected to grow at a CAGR of 12.4% from 2025 to 2030. Another source indicates the global tangential flow filtration market size was valued at USD 2.35 billion in 2025, projected to grow to USD 6.84 billion by 2034, exhibiting a CAGR of 12.58%. North America accounted for a 40.4% revenue share of the tangential flow filtration market in 2024. For hollow fiber filtration specifically, the global market was valued at USD 0.92 billion in 2025 and is projected to grow to USD 3.23 billion by 2034, exhibiting a CAGR of 15.01%. North America dominated the global hollow fiber filtration market with a 42.64% revenue share in 2024.
- Process Analytics Products (SoloVPE, FlowVPE, FlowVPX slope spectroscopy systems): The global biopharmaceutical process analytical technology market was valued at US$1.2 billion in 2024 and is projected to reach US$2.6 billion by 2029, advancing at a CAGR of 16.0%. The global bioprocess analyzers market size was valued at USD 2.5 billion in 2025 and is projected to grow from USD 2.8 billion in 2026 to USD 7.8 billion by 2035, expanding at a CAGR of 12.2%. North America is the largest market for bioprocess analyzers. The global process spectroscopy market size was valued at USD 21.3 billion in 2023 and is expected to reach USD 35.8 billion by 2033, growing at a CAGR of 5.33%. North America led the process spectroscopy market in 2025 with a 32.90% share.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Repligen (RGEN)
- Continued Strength in Analytics and Proteins Franchises: Repligen anticipates sustained high growth from its analytics and proteins divisions. In Q4 2025, both franchises grew by over 30% year-over-year. The company projects its analytics franchise to grow by more than 20% in 2026, while its proteins division is expected to achieve low double-digit growth. This growth is aligned with Repligen's strategic focus on expanding its product offerings.
- New Product Launches and Innovation: A key driver of future revenue growth is Repligen's commitment to innovation and the introduction of new products. The company plans strategic initiatives, including R&D spending to launch innovative products, such as the SoloVPE PLUS analytics platform and new AVIPure resins designed for the new modality market.
- Geographic Expansion and Enhanced Commercial Strategies: Repligen is focused on expanding its commercial presence, particularly through building out its presence in the Asia Pacific (APAC) region. Additionally, the company is intensifying its commercial investments in cross-selling to existing customers and achieving further penetration in key accounts, demonstrated by selling 2.5 times as many product lines to these customers compared to 2019.
- Growth in New Modalities within the Bioprocessing Market: Despite a short-term headwind related to a gene therapy platform, Repligen is positioned to benefit from the rapidly expanding market for new modalities. The company's diversified portfolio supports the demand for biologics and newer modalities, which is expected to drive solid consumables and equipment revenue. The bioprocessing market for new modalities is projected to have a high compounded annual growth rate (CAGR) of over 30%.
AI Analysis | Feedback
Share Repurchases
- In 2024, Repligen repurchased 92,090 shares of its common stock for $14.4 million.
Share Issuance
- The company issued $600 million in 1.00% Convertible Senior Notes due 2028 in 2024 to refinance existing debt and support strategic initiatives.
Outbound Investments
- In 2025, Repligen acquired the bioprocessing analytics portfolio from 908 Devices for $69.9 million in cash, which included desktop devices for real-time process monitoring, control, and analysis.
- In 2024, Repligen expanded its manufacturing capabilities through the acquisition of Tantti Laboratory Inc.
- In 2023, the company acquired Metenova, which offers magnetic mixing and drive train technologies, and FlexBiosys, Inc., further strengthening its fluid management portfolio.
- In 2021, Repligen acquired Avitide Inc. for approximately $150 million, consisting of $75 million in cash and $75 million in Repligen common stock, to enhance its affinity ligand discovery engine and chromatography development.
Capital Expenditures
- Repligen's capital expenditures were $23 million in 2025, $26 million in 2024, $36 million in 2023, $85 million in 2022, and $67 million in 2021.
- The company's capital expenditures in Q4 2025 were $8.2 million, focused on funding long-term assets and infrastructure.
- Repligen continues to make investments to support sustainable future growth, including in new technologies, capacity, and geographic expansion, as part of balancing margin expansion with growth initiatives for 2026.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Repligen Earnings Notes | 12/29/2026 | |
| Can Repligen Stock Hold Up When Markets Turn? | 10/17/2025 | |
| How Does Repligen Stock Stack Up Against Its Peers? | 08/13/2025 | |
| RGEN Dip Buy Analysis | 07/10/2025 | |
| Repligen Total Shareholder Return (TSR): -19.9% in 2024 and -18.4% 3-yr compounded annual returns (below peer average) | 03/07/2025 | |
| Repligen (RGEN) Operating Cash Flow Comparison | 02/17/2025 | |
| Repligen (RGEN) Net Income Comparison | 02/16/2025 | |
| Repligen (RGEN) Operating Income Comparison | 02/15/2025 | |
| ARTICLES | ||
| What’s Next For Repligen Stock After A 12% Fall In A Month? | 10/11/2021 |
Trade Ideas
Select ideas related to RGEN.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
| 06302024 | RGEN | Repligen | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 15.5% | -1.3% | -13.6% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 120.10 |
| Mkt Cap | 32.6 |
| Rev LTM | 7,065 |
| Op Inc LTM | 1,456 |
| FCF LTM | 993 |
| FCF 3Y Avg | 1,318 |
| CFO LTM | 1,396 |
| CFO 3Y Avg | 1,685 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.9% |
| Rev Chg 3Y Avg | -0.2% |
| Rev Chg Q | 7.0% |
| QoQ Delta Rev Chg LTM | 1.7% |
| Op Mgn LTM | 19.1% |
| Op Mgn 3Y Avg | 20.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 19.8% |
| CFO/Rev 3Y Avg | 23.4% |
| FCF/Rev LTM | 14.1% |
| FCF/Rev 3Y Avg | 19.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 32.6 |
| P/S | 5.5 |
| P/EBIT | 29.8 |
| P/E | 37.1 |
| P/CFO | 23.7 |
| Total Yield | 2.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.3% |
| D/E | 0.1 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 4.2% |
| 3M Rtn | -20.3% |
| 6M Rtn | -6.0% |
| 12M Rtn | 10.1% |
| 3Y Rtn | -14.9% |
| 1M Excs Rtn | -0.5% |
| 3M Excs Rtn | -17.6% |
| 6M Excs Rtn | -9.0% |
| 12M Excs Rtn | -22.4% |
| 3Y Excs Rtn | -81.1% |
Comparison Analyses
Price Behavior
Price Behavior
| Market Price | $120.10 | |
| Market Cap ($ Bil) | 6.8 | |
| First Trading Date | 03/26/1990 | |
| Distance from 52W High | -30.3% | |
| 50 Days | 200 Days | |
| DMA Price | $127.38 | $138.20 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -5.7% | -13.1% |
| 3M | 1YR | |
| Volatility | 39.6% | 43.4% |
| Downside Capture | 1.24 | 1.00 |
| Upside Capture | 117.23 | 138.75 |
| Correlation (SPY) | 47.0% | 44.1% |
RGEN Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.91 | 1.66 | 1.56 | 1.57 | 1.45 | 1.42 |
| Up Beta | 3.84 | 0.97 | 1.89 | 1.50 | 1.52 | 1.48 |
| Down Beta | 0.64 | 0.76 | 0.40 | 0.89 | 1.11 | 1.27 |
| Up Capture | 238% | 146% | 139% | 216% | 172% | 181% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 10 | 16 | 27 | 59 | 118 | 360 |
| Down Capture | 197% | 227% | 223% | 163% | 141% | 110% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 12 | 26 | 36 | 67 | 133 | 389 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RGEN | |
|---|---|---|---|---|
| RGEN | 12.6% | 46.4% | 0.39 | - |
| Sector ETF (XLV) | 12.3% | 16.8% | 0.52 | 55.4% |
| Equity (SPY) | 31.2% | 17.3% | 1.47 | 54.1% |
| Gold (GLD) | 60.1% | 27.8% | 1.69 | 11.9% |
| Commodities (DBC) | 29.8% | 16.6% | 1.58 | 16.8% |
| Real Estate (VNQ) | 21.3% | 15.2% | 1.07 | 44.8% |
| Bitcoin (BTCUSD) | -4.3% | 43.7% | 0.02 | 28.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RGEN | |
|---|---|---|---|---|
| RGEN | -9.4% | 49.9% | -0.02 | - |
| Sector ETF (XLV) | 6.3% | 14.6% | 0.25 | 46.5% |
| Equity (SPY) | 11.1% | 17.0% | 0.50 | 48.4% |
| Gold (GLD) | 22.1% | 17.8% | 1.02 | 11.1% |
| Commodities (DBC) | 11.8% | 18.8% | 0.52 | 7.1% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 42.4% |
| Bitcoin (BTCUSD) | 4.3% | 56.5% | 0.30 | 22.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RGEN | |
|---|---|---|---|---|
| RGEN | 16.4% | 45.6% | 0.50 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 47.7% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 46.4% |
| Gold (GLD) | 14.2% | 15.9% | 0.74 | 8.8% |
| Commodities (DBC) | 8.6% | 17.6% | 0.41 | 8.9% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.22 | 33.8% |
| Bitcoin (BTCUSD) | 67.6% | 66.9% | 1.07 | 13.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/24/2026 | -0.5% | -7.7% | -14.1% |
| 10/28/2025 | -5.9% | -6.8% | 6.6% |
| 7/29/2025 | 4.7% | -2.6% | 0.7% |
| 2/20/2025 | 7.9% | 8.0% | -7.6% |
| 11/12/2024 | 6.5% | -11.5% | 11.3% |
| 7/30/2024 | 16.4% | 17.5% | 5.8% |
| 5/1/2024 | -3.6% | 2.1% | -9.8% |
| 2/21/2024 | -2.8% | -3.5% | -1.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 13 | 13 |
| # Negative | 6 | 7 | 7 |
| Median Positive | 8.0% | 8.0% | 5.8% |
| Median Negative | -3.2% | -5.7% | -7.6% |
| Max Positive | 17.9% | 26.1% | 39.7% |
| Max Negative | -5.9% | -11.5% | -14.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 03/14/2025 | 10-K |
| 09/30/2024 | 11/18/2024 | 10-Q |
| 06/30/2024 | 07/30/2024 | 10-Q |
| 03/31/2024 | 05/01/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 10/31/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/02/2023 | 10-Q |
| 12/31/2022 | 02/22/2023 | 10-K |
| 09/30/2022 | 11/01/2022 | 10-Q |
| 06/30/2022 | 08/02/2022 | 10-Q |
| 03/31/2022 | 04/27/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dawes, Karen A | Direct | Sell | 12182025 | 161.00 | 275 | 44,275 | 14,783,181 | Form | |
| 2 | Loeillot, Olivier | Chief Executive Officer | Direct | Sell | 11262025 | 170.00 | 7,041 | 1,196,970 | 6,102,660 | Form |
| 3 | Bylund, James | Chief Operating Officer | Direct | Sell | 11192025 | 151.21 | 2,191 | 331,301 | 3,254,039 | Form |
| 4 | Hunt, Anthony | Direct | Sell | 11142025 | 154.61 | 20,000 | 3,092,278 | 12,483,992 | Form | |
| 5 | Hunt, Anthony | Direct | Sell | 11132025 | 156.88 | 25,000 | 3,921,940 | 15,804,319 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.